Every material Form 8-K RAPID MICRO BIOSYSTEMS, INC. has filed with the SEC since May 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Rapid Micro Biosystems reported second quarter 2026 total revenue of $8.1 million, up 10.9% from $7.3 million a year earlier, and a gross margin of 15.0%, compared with 3.8% in the prior-year quarter. The net loss widened to $12.9 million from $11.9 million, while loss per share was unchanged at $0.27, and the company reaffirmed its full-year 2026 revenue guidance of $37.0 million to $41.0 million.
Q2 2026 total revenue $8.1 million, up 10.9% from $7.3 million in Q2 2025
Net loss $12.9 million versus $11.9 million a year earlier; net loss per share $0.27 in both periods
Gross margin 15.0% versus 3.8% in Q2 2025; total operating expenses rose 8.9% to $13.5 million
Full-year 2026 revenue guidance of $37.0 million to $41.0 million reaffirmed; validation guidance raised to at least 27 from 25
Rapid Micro Biosystems entered into an underwritten offering of about 5 million shares of Class A common stock, including pre-funded warrants, with accompanying Series A and Series B warrants, plus a concurrent sale to directors and officers. The company estimates net proceeds of about $8.9 million for working capital and general corporate purposes. The new shares and warrants add to the number of shares outstanding, which dilutes existing shareholders, while the cash raised supports the company's working capital.
3,581,000 Class A common shares plus pre-funded warrants for up to 1,463,000 shares, sold with warrants at a combined price of $1.955 per share
Series A warrants exercisable at $1.955 and Series B warrants exercisable at $2.340, both exercisable six months after issuance
Estimated net proceeds of about $8.9 million; the offering is expected to close on May 20, 2026
Concurrent sale of 71,607 shares to directors and officers for gross proceeds of about $140,000
Rapid Micro Biosystems reported first quarter 2026 total revenue of $8.0 million, up 11.1% from a year earlier, with product revenue up 36.0%. The net loss widened to $14.3 million from $11.3 million, and the company reaffirmed its full year 2026 total revenue guidance of $37.0 million to $41.0 million. For shareholders, revenue growth is offset by a larger loss and cash, short-term investments and restricted cash of about $23 million as of March 31, 2026.
Total revenue rose 11.1% to $8.0 million; product revenue rose 36.0% to $5.6 million, while service revenue fell 21.9% to $2.4 million.
Net loss was $14.3 million, or $0.31 per share, versus $11.3 million, or $0.26 per share, in the first quarter of 2025.
Full year 2026 total revenue guidance of $37.0 million to $41.0 million was reaffirmed, along with a gross margin target of approximately 20%.
Cash, short-term investments and restricted cash were about $23 million on March 31, 2026, down from $38.6 million on December 31, 2025.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every RAPID MICRO BIOSYSTEMS, INC. filing is on SEC EDGAR ↗. 8-K briefs of other companies →